Arcutis Biotherapeutics Inc.

23.18-0.7400-3.09%Vol 204.12K1Y Perf -6.17%
Sep 24th, 2021 16:00 DELAYED
BID23.18 ASK23.27
Open23.45 Previous Close23.92
Pre-Market- After-Market-
 - -  - -%
Target Price
57.20 
Analyst Rating
Strong Buy 1.00
Potential %
146.76 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
27.03 
Earnings Rating
Market Cap1.16B 
Earnings Date
4th Nov 2021
Alpha0.01 Standard Deviation0.20
Beta0.26 

Today's Price Range

22.7824.13

52W Range

17.5138.49

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
2.25%
1 Month
11.07%
3 Months
-15.37%
6 Months
-17.77%
1 Year
-6.17%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ARQT23.18-0.7400-3.09
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.91-0.847.69
Q01 2021--0.76-
Q04 2020-0.89-0.7911.24
Q03 2020-0.95-1.01-6.32
Q02 2020--0.94-
Q01 2020--1.15-
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date4th Nov 2021
Estimated EPS Next Report-1.09
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume204.12K
Shares Outstanding50.24M
Shares Float20.92M
Trades Count2.82K
Dollar Volume6.52M
Avg. Volume220.82K
Avg. Weekly Volume139.37K
Avg. Monthly Volume188.81K
Avg. Quarterly Volume177.63K

Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) stock closed at 23.18 per share at the end of the most recent trading day (a -3.09% change compared to the prior day closing price) with a volume of 204.12K shares and market capitalization of 1.16B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 54 people. Arcutis Biotherapeutics Inc. CEO is Todd Franklin Watanabe.

The one-year performance of Arcutis Biotherapeutics Inc. stock is -6.17%, while year-to-date (YTD) performance is -17.6%. ARQT stock has a five-year performance of %. Its 52-week range is between 17.51 and 38.49, which gives ARQT stock a 52-week price range ratio of 27.03%

Arcutis Biotherapeutics Inc. currently has a PE ratio of -6.80, a price-to-book (PB) ratio of 2.75, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.21%, a ROC of -47.55% and a ROE of -48.22%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Arcutis Biotherapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.09 for the next earnings report. Arcutis Biotherapeutics Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Arcutis Biotherapeutics Inc. is Strong Buy (1), with a target price of $57.2, which is +146.76% compared to the current price. The earnings rating for Arcutis Biotherapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arcutis Biotherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arcutis Biotherapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.24, ATR14 : 1.30, CCI20 : 152.73, Chaikin Money Flow : 0.16, MACD : 0.37, Money Flow Index : 58.21, ROC : 13.07, RSI : 56.16, STOCH (14,3) : 77.27, STOCH RSI : 0.52, UO : 60.92, Williams %R : -22.73), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arcutis Biotherapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The firm's lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.

CEO: Todd Franklin Watanabe

Telephone: +1 805 418-5006

Address: 2945 Townsgate Road, Westlake Village 91361, CA, US

Number of employees: 54

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

63%37%

Bearish Bullish

69%31%

News

Stocktwits